(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 September 2025 (18.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/194154 A1

(51) International Patent Classification:
G16H 20/10 (2018.01) *G06K 19/06* (2006.01)
G16H 40/20 (2018.01) *G06Q 10/08* (2012.01)
H04W 12/47 (2021.01)

(21) International Application Number:
PCT/US2025/020112

(22) International Filing Date:
14 March 2025 (14.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/565,433	14 March 2024 (14.03.2024)	US
63/565,444	14 March 2024 (14.03.2024)	US
63/666,599	01 July 2024 (01.07.2024)	US

(71) Applicants: **MERCK SHARP & DOHME LLC** [US/US]; 126 East Lincoln Ave., RY86-2011A, Rahway, NJ 07065 (US). **MSD INTERNATIONAL GMBH** [CH/CH]; Tribschensbrasse 60, 6005 Lucerne (CH).

(72) Inventors: **FERNANDES, Rui, Miguel Jeronimo**; MSD International GmbH, Tribschensbrasse 60, 6005 Lucerne (CH). **PAIS, Lavina, L.**; Merck Sharp & Dohme LLC, 126 East Lincoln Ave., RY86-2011A, Rahway, NJ 07065 (US). **ENGLAND, Jeffrey, M.**; Merck Sharp & Dohme LLC, 126 East Lincoln Ave., RY86-2011A, Rahway, NJ 07065 (US). **MARAULI, Martina**; MSD International GmbH, Tribschensbrasse 60, 6005 Lucerne (CH). **SHULTZ TERKHORN, Carol, Ann**; Merck Sharp & Dohme LLC, 126 East Lincoln Ave., RY86-2011A, Rahway, NJ 07065 (US). **BROUILLARD, Jamie, Ann**; Merck Sharp & Dohme LLC, 126 East Lincoln Ave., RY86-2011A, Rahway, NJ 07065 (US). **TRIVEDI, Maalav, Bharat**; Merck Sharp & Dohme LLC, 126 East Lincoln Ave., RY86-2011A, Rahway, NJ 07065 (US). **DEBETS, Alexander, Johannes Jozef**; MSD International GmbH, Tribschensbrasse 60, 6005 Lucerne (CH).

(74) Agent: **PATEL, Rajiv, P.** et al.; Fenwick & West LLP, 801 California Street, Mountain View, CA 94041 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: SYSTEM FOR MEDICINAL SUPPLY MONITORING AND MANAGEMENT




FIG. 1

(57) Abstract: A medicinal supply management system manages distribution of medicinal supply. The system may implement a pooling algorithm for pooling studies together, across different countries, with different protocol labeling parameters and/or blinding parameters. The system may allocate unique identifiers for the pooled studies. The system may implement digital display labels on the medicinal product for up-to-date presentation of relevant information to healthcare providers administering the medicinal product. The system may further implement controlled packaging for maintaining proper storage of the medicinal product, e.g., during transport to the treatment site. The controlled packaging may further include sensors for monitoring the internal environment of the controlled packaging, to maintain proper storage of the medicinal product.

WO 2025/194154 A1

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*